According to Perrigo's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.915763. At the end of 2023 the company had a P/S ratio of 0.9367.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.9367 | -9.15% |
2022 | 1.03 | -18% |
2021 | 1.26 | -10.92% |
2020 | 1.41 | -2.89% |
2019 | 1.45 | 30.6% |
2018 | 1.11 | -55.16% |
2017 | 2.48 | 4.96% |
2016 | 2.36 | -38.91% |
2015 | 3.87 | -31.4% |
2014 | 5.64 | 4.48% |
2013 | 5.40 | 80.21% |
2012 | 3.00 | -2.19% |
2011 | 3.06 | 31.96% |
2010 | 2.32 | 35.98% |
2009 | 1.71 | 14.35% |
2008 | 1.49 | -28.97% |
2007 | 2.10 | 83.49% |
2006 | 1.15 | 0.68% |
2005 | 1.14 | -15.04% |
2004 | 1.34 | 2.6% |
2003 | 1.31 | 26.97% |
2002 | 1.03 | -3.5% |
2001 | 1.07 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
United Therapeutics UTHR | 4.92 | 437.10% | ๐บ๐ธ USA |
Endo International
ENDPQ | 0.0000 | -99.99% | ๐ฎ๐ช Ireland |
Intercept Pharmaceuticals
ICPT | 2.50 | 173.16% | ๐บ๐ธ USA |
Catalent CTLT | 2.49 | 172.01% | ๐บ๐ธ USA |